Internationalization of Traditional/Complementary Medicine products: market entry as medicine

Abstract

Internationalization of Traditional/Complementary Medicine (T&CM) products is important for initiating and sustaining developments in this field. Particularly for traditional Chinese medicines (TCMs), the global market continues to expand due to an interest in the potential clinical benefits of traditional approaches that are largely considered lower risk and lower cost than many conventional treatments. While the benefits of internationalization hold clear advantages for the business of T&CM products, keeping abreast of regulatory processes in different countries and regions that regularly revise market entry requirements is challenging. At present, the regulations of T&CM products are country specific and largely based on a risk-based assessment with a focus on protecting the consumer. To date, systematic analysis of these regulatory differences between countries and regions is limited. Publically available information about the legal requirements for the market entry of T&CM products were obtained from the relevant regulatory authority’s websites for selected countries and regions (Macau-China, Hong Kong-China, Singapore, Australia, Canada, the European countries and the US). The market entry requirements in terms of quality, safety and efficacy of T&CM products for each country were analyzed and compared. Major differences were identified in the classification of T&CM products, market entry pathways, requirements of compliance with Good Manufacturing Practices; and level of evidence to demonstrate safety and efficacy based on historical use, non-clinical and clinical studies. Variations in the evaluation standards adopted by regulatory authorities pose a number of barriers and opportunities for the internationalization of T&CM products and have great implications for internationalization of TCMs from the sponsors’ and the regulators’ perspectives.

Regioisomerism and 5-substitution as promising approaches for molecular design of safer acetaminophen derivatives

“…The acute toxicity oral test was performed according to the Organization for Economic Cooperation and Development (OECD) guideline 420 [54] and Brazilian Health Regulatory Agency [55], with initial dose at 300 mg/kg. The animals were divided into four groups: control 300 mg/kg (n = 2), treated 300 mg/kg (n = 4), control 2000 mg/kg (n = 2), treated 2000 mg/kg (n = 4).…”

Analysis on the current quality standards of Chinese materia Medica used in COVID-19 prevention and treatment

“…Through the coordination of pharmacopoeia standards, global free trade of high-quality pharmaceutical products can be promoted. Although TCM has been widely promoted globally, due to the inherent characteristics of CMM and the sparks between traditional and modern evaluation systems, CMM has been variously identified in different countries and has difficulties in international registration [20][21][22]. The phenomena mainly result from the barriers to connect the quality standards for CMM with the mainstream markets in Europe and US, and restrictions of medical regulations and policies in different countries/ regions.…”

The prevalence, perceptions and behaviors associated with traditional/complementary medicine use by breastfeeding women living in Macau: a cross-sectional survey study

“…However, the efficacy and safety of commonly used herbs remained uncertain. This is mainly because many studies on safety or efficacy of T/CM were of poor methodological quality [4] and regulatory standards regarding market entry of these products vary greatly from one country to another [5]. While traditional evidence is a 'time honored' system of handing down knowledge and practices, there remains a need to further evaluate this knowledge and experience within a scientific paradigm to establish both efficacy and safety data [6].…”